2023
Recent Key Studies in Cancers of the Uterine Corpus and Cervix: New Updates in Immunotherapy, the Microbiome, Bone Density, Quantifying Lymphovascular Invasion, and Hypofractionated Pelvic Radiation Therapy.
Harkenrider M, Fields E, Chopra S, Damast S, Kidd E, Chino J. Recent Key Studies in Cancers of the Uterine Corpus and Cervix: New Updates in Immunotherapy, the Microbiome, Bone Density, Quantifying Lymphovascular Invasion, and Hypofractionated Pelvic Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2023, 115: 269-275. PMID: 36621226, DOI: 10.1016/j.ijrobp.2022.07.1833.Peer-Reviewed Original Research
2017
Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer
Lester-Coll NH, Young MR, Park HS, Ratner ES, Litkouhi B, Damast S. Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer. International Journal Of Gynecological Cancer 2017, 27: 1904-1911. PMID: 28763364, DOI: 10.1097/igc.0000000000001095.Peer-Reviewed Original ResearchConceptsReceipt of chemotherapyEndometrioid endometrial carcinomaNational Cancer Data BaseImproved overall survivalRole of chemotherapyOverall survivalAdjuvant chemotherapyAdjuvant treatmentStage II endometrial cancerCox proportional hazards regressionPropensity scoreAdjuvant therapy useGrade 3 diseaseStage II patientsProportional hazards regressionWorse overall survivalMultivariable logistic regressionKaplan-Meier estimatesLog-rank testAdjuvant radiotherapyExcellent prognosisLymphovascular invasionObservational cohortEEC patientsEndometrial cancer